Boehringer Ingelheim goes “Blue” in supporting World Diabetes Day activities
15 November 2013 | By Boehringer Ingelheim
"Run for Diabetes" raises €15,000 towards supporting "Life for a Child Programme..."
List view / Grid view
News
Novartis announces positive clinical trial results for novel H7N9 vaccine
14 November 2013 | By Novartis
85% of subjects immunologically protected after receiving second dose of investigational cell culture vaccine when combined with proven MF59® adjuvant...
Bristol-Myers Squibb Foundation marks World Diabetes Day with four grants addressing link between diabetes, depression and distress
14 November 2013 | By Bristol-Myers Squibb
“There is a need for the development of short- and long-term diabetes care models and self-management programs..."
Amgen to highlight new Evolocumab (AMG 145) data at upcoming American Heart Association Scientific Sessions 2013
14 November 2013 | By Amgen
First long-term data of a PCSK9 Inhibitor to be featured in clinical science: special reports session...
Boehringer Ingelheim submits applications in Europe to extend the indication for the use of tiotropium Respimat® to the treatment of asthma in adults aged 18 years and over
13 November 2013 | By Boehringer Ingelheim
"Our extensive studies have demonstrated that tiotropium Respimat® has the potential to be an effective new treatment..."
Leading hematology journal publishes pivotal ELOCTATE™ data that demonstrated efficacy and safety of investigational long-lasting therapy for hemophilia A
13 November 2013 | By Biogen Idec
Phase 3 study showed potential for once- or twice-weekly prophylactic dosing regimens...
IMBRUVICA™ (ibrutinib) capsules now approved in the U.S. for Mantle Cell Lymphoma patients who have received at least one prior therapy
13 November 2013 | By Johnson & Johnson
Janssen Biotech, Inc. [“Janssen”] today announced the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA™ (ibrutinib) capsules for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.1 This indication is based on overall response rate (ORR). An improvement in survival or…
Abbott supports relief efforts in the Philippines
13 November 2013 | By Abbott
The Abbott Fund provide $450,000 in grants and healthcare products to help people affected by super typhoon...
A turnkey solution for forensic identification from Tecan
12 November 2013 | By kdm communications
Genia Geo has chosen Tecan’s HID EVOlution™ system as part of its comprehensive forensic identification services for governments around the world...
Tiësto teams up with Music Saves Lives® and Abbott to encourage young people to donate blood
With advances in medical treatments and an aging population, the demand for donated blood continues, as fewer people are becoming lifelong donors. 1In an effort to raise awareness about blood donation and encourage young adults to become repeat blood donors, Music Saves Lives® and Abbott are announcing a special opportunity…
Simeprevir administered once daily demonstrates sustained virologic response in genotype 1 chronic hepatitis C patients
11 November 2013 | By Janssen Therapeutics EMEA
HCV is a major problem in the EMEA region, where an estimated 15 million people are living with the disease...
Novartis announces divestiture of its blood transfusion diagnostics unit to Grifols
11 November 2013 | By Novartis
Spain-based Grifols to acquire Novartis blood transfusion diagnostics unit for USD 1.675 billion...
Micardis crosses 50 million patient-years of experience on 15th anniversary
11 November 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announces clinical experience with its angiotensin II receptor blocker (ARB) has reached 50 million patient-years of real world experience...
AstraZeneca to invest £120 million in new manufacturing facility to produce Zoladex in Macclesfield
11 November 2013 | By AstraZeneca
Zoladex has been manufactured at AstraZeneca’s Macclesfield plant for over 25 years, supplying the medicine to more than one hundred markets around the world...
Merck’s investigational grass sublingual allergy immunotherapy tablet significantly reduced allergy symptoms and need for symptom-relief medication in adults and children
9 November 2013 | By Merck
“Patients in this study who took the investigational Timothy grass sublingual allergy immunotherapy tablet showed a significant improvement in common allergy symptoms..."
